A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Subjects 6 Years and Older and F/MF Genotypes
A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Subjects 6 Years and Older and F/MF Genotypes
This study will evaluate the long-term safety and efficacy of elexacaftor (ELX)/tezacaftor
 (TEZ)/ivacaftor (IVA) triple combination (TC) in subjects with CF who are 6 years of age and
 older with F/MF genotypes.
Key Inclusion Criteria:

 -  Completed study drug treatment in parent study (VX19-445-116, NCT04353817), or had
 study drug interruption(s) in parent study but completed study visits up to the last
 scheduled visit of the treatment period in the parent study

 Key Exclusion Criteria:

 -  History of study drug intolerance in the parent study

 Other protocol defined Inclusion/Exclusion criteria may apply